ALI PHARMA CARE CORPORATE LTD

Executive Summary

ALI PHARMA CARE CORPORATE LTD operates within the human health sector as a micro-entity with a consistent filing record and relevant director expertise. However, its financial position shows declining net assets and a liquidity deficit, indicating medium risk regarding its ability to meet short-term obligations and maintain solvency without additional capital or improved cash flow. Further analysis of cash flows and liabilities is recommended to clarify the company’s financial resilience.

ALI PHARMA CARE CORPORATE LTD - Analysis Report

Company Number: 13435753

Analysis Date: 2025-07-20 13:13 UTC

1. Risk Rating: MEDIUM
   Despite being an active company in the healthcare sector with consistent filings and no overdue returns, the company exhibits signs of financial fragility. Net assets have declined from £272 in 2021 to £106 in 2024, indicating limited equity buffer. Current liabilities exceed current assets, resulting in negative net current assets, which signals potential liquidity stress.

2. Key Concerns:

• Liquidity Deficit: The balance sheet shows current liabilities (£12,633) exceeding current assets (£11,247) for 2024, suggesting challenges in meeting short-term obligations without additional funding or asset sales.
• Declining Net Assets: A steady decrease in net assets over the past four years points to erosion of shareholder equity, which could impair solvency if trends continue.
• Minimal Capital and Size: Share capital is only £100, and the company is a micro-entity with a single employee, possibly limiting operational scale and financial resilience.

3. Positive Indicators:

• Timely Filing and Compliance: All accounts and confirmation statements are up to date with no overdue filings, indicating good regulatory compliance and governance discipline.
• Consistent Operational Activity: The company has maintained active status since incorporation in 2021 and continues to generate current assets, showing ongoing business activity.
• Director With Relevant Expertise: The director’s occupation as a pharmacist suggests relevant sector knowledge, which may support operational stability.

4. Due Diligence Notes:

• Review cash flow statements and bank balances to assess actual liquidity beyond balance sheet figures.
• Investigate the nature and terms of current liabilities to understand repayment obligations and any contingent risks.
• Examine business model sustainability given the micro-entity scale and limited fixed assets.
• Confirm if there are related party transactions or director loans affecting financial position.
• Ascertain whether provisions for liabilities reflect any pending legal or regulatory issues.